• Baker's yeast

    Minnesota Partnership Researchers Uncover Cancer Drug Prospects

    Clues to possible drugs for two rare cancers through research involving baker’s yeast and a library of chemical compounds.

    Read more

  • Gunda George

    Gamechanger: Gunda Georg

    Gunda Georg is an esteemed researcher and professor who has made a tremendous impact in the field of synthetic medicinal chemistry.

    Read more

  • Abstract image

    Gunda Georg Inducted into the Academy for Excellence in Health Research

    The Academy for Excellence in Health Research is the highest recognition of excellence in research by Academic Health Center faculty

    Read more

  • Gunda Georg, and Vadim JGurvich

    Welcome to the Institute for Therapeutics Discovery & Development

    ITDD creates opportunities for drug discovery and early pre-clinical drug development through collaborations between various schools, colleges and research centers, as well as industrial throughout Minnesota and nationwide.

    Learn more about our scientific services

  • pills

    Hormone-Free Birth Control Research Advances

    Researchers will investigate pharmaceutical alternatives to existing hormone-based birth control under a new $8.3M NIH contract.

 The Journal of Medicinal Chemistry

The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

See journal


Dr. Vadim Gurvich receives R01 funding

Vadim Gurvich, ITDD Associate Director, received $68,400 for his part of an R01 project, "Toward a Mechanism-Based Approach to Treating Atrial Fibrillation." Dr.

Peter Dosa Featured in College of Pharmacy annual report

The College of Pharmacy's 2014 annual report highlights associate program director Peter Dosa's research in "


Dr. Vadim Gurvich will co-lead new NIH program to accelerate new inventions to the market

The University of Minnesota has been selected by the National Institutes of Health as one of three Research Evaluation and Commercialization Hub (REACH) sites nationally to establish a university-


Special announcements


"Transformation of Pharmaceutical R&D and the Increasing Opportunities for Academic Scientists" Presented by Bernard Munos

Friday, November 20, 2015 - 11:00 a.m.—12:00 p.m.

Gunda GeorgGunda I. Georg, Ph.D.

Director, Institute for Therapeutics Discovery and Development
Professor and Department Head, Department of Medicinal Chemistry; Robert Vince Endowed Chair; McKnight Presidential Chair

Dr. Georg’s expertise includes synthetic medicinal agents, natural products chemistry, and the development of new synthetic methods. She is the co-inventor of Lusedra® and several other drug candidates, as well as the co-founder of ProQuest Pharmaceuticals, Inc. (now a part of Eisai Pharmaceuticals). The ITDD core directors have extensive academic and industrial drug discovery and development expertise. The group uses advanced research and development techniques, including high through-put screening, structure-based drug design, computer modeling, chem- and bioinformatics methods, and animal models to translate basic biomedical discoveries towards new approaches for prevention, treatment, and cures

Vadim GurvichVadim J. Gurvich, Ph.D., M.B.A.

Associate Director, Institute for Therapeutics Discovery and Development
Director, Chemical Process Development Core

Michael WaltersMichael A. Walters, Ph.D.

Director, Lead and Probe Discovery Core
Institute for Therapeutics Discovery and Development